4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol has been researched along with fulvestrant in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bryant, HU; Cullinan, GJ; Glasebrook, AL; Hauser, KL; Muehl, BS; Palkowitz, AD; Pell, TR; Phillips, DL; Sato, M; Shetler, PK; Short, LL; Thrasher, KJ | 1 |
| Bélanger, A; Caron, B; Cloutier, J; Dory, YL; Favre, A; Gauthier, S; Labrie, C; Labrie, F; Larouche, D; Leblanc, G; Mailhot, J; Martel, C; Mérand, Y; Ouellet, C; Schwerdtfeger, A; Simard, J | 1 |
| Dunn-Dufault, R; Feher, M; Kalbakji, A; Mercure, J; Pagé, M; Peter, MG; Redden, PR; Schmidt, JM; Tremblay, GB | 1 |
| Bellavance, E; Luu-The, V; Poirier, D | 1 |
| Bhatnagar, D; Boue, SM; Burow, ME; Collins-Burow, BM; Driver, J; Elliott, S; Jiang, Q; McLachlan, JA; Payton-Stewart, F; Rhodes, LV; Sridhar, J; Stevens, C; Wang, G; Wiese, TE; Zhang, Q; Zheng, S | 1 |
| Bearss, NR; Bhatnagar, D; Boue, SM; Burow, ME; Cleveland, TE; Erhardt, PW; Khupse, RS; Reese, MD; Sarver, JG; Trendel, JA; Wiese, TE | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Grillot, K; Hager, JH; Heyman, R; Joseph, JD; Julien, J; Kahraman, M; Kaufman, J; Lai, A; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
| Andrews, DM; Ballard, P; Bradbury, RH; Buttar, D; Callis, RJ; Currie, GS; Curwen, JO; Davies, CD; de Almeida, C; De Savi, C; Donald, CS; Feron, LJ; Gingell, H; Glossop, SC; Hayter, BR; Hussain, S; Karoutchi, G; Lamont, SG; MacFaul, P; Moss, TA; Norman, RA; Pearson, SE; Rabow, AA; Tonge, M; Walker, GE; Weir, HM; Wilson, Z | 1 |
| Abrams, T; Baird, J; Burks, HE; Fekete, A; Hamann, LG; Kim, S; Kirby, CA; Lombardo, F; Loo, A; Lubicka, D; Macchi, K; McDonnell, DP; Mishina, Y; Norris, JD; Nunez, J; Peukert, S; Saran, C; Sun, Y; Thomsen, NM; Wang, C; Wang, J | 1 |
| Barrett, I; Carr, M; Fayne, D; Greene, LM; Keely, NO; Knox, AJS; Meegan, MJ; O'Boyle, NM; Twamley, B; Zisterer, DM | 1 |
| Aparicio, A; Bonnefous, C; Brigham, D; Darimont, B; Douglas, K; Govek, S; Hager, JH; Heyman, R; Joseph, JD; Kahraman, M; Kaufman, J; Lai, A; Lee, K; Lu, N; Maheu, K; Nagasawa, J; Prudente, R; Qian, J; Rix, PJ; Sensintaffar, J; Shao, G; Smith, ND | 1 |
11 other study(ies) available for 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol and fulvestrant
| Article | Year |
|---|---|
Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)]b enzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator.
Topics: Animals; Breast Neoplasms; Cell Division; Estrogen Antagonists; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Molecular Structure; Piperidines; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Tumor Cells, Cultured | 1997 |
(S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)-ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen.
Topics: Administration, Oral; Animals; Benzopyrans; Binding, Competitive; Breast Neoplasms; Cytosol; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Female; Humans; Mice; Molecular Structure; Ovariectomy; Piperidines; Propionates; Raloxifene Hydrochloride; Receptors, Estrogen; Stereoisomerism; Structure-Activity Relationship; Uterus | 1997 |
De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor.
Topics: Animals; Binding, Competitive; Cell Division; Cell Line; Chlorocebus aethiops; Computer Simulation; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Humans; Ligands; Models, Molecular; Phenanthrenes; Radioligand Assay; Receptors, Estrogen; Structure-Activity Relationship; Transcription, Genetic; Tumor Cells, Cultured | 2003 |
Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.
Topics: 17-Hydroxysteroid Dehydrogenases; Androstane-3,17-diol; Androstanes; Biocatalysis; Cell Line; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Estrone; Humans; Inhibitory Concentration 50; Oxidation-Reduction; Substrate Specificity | 2009 |
Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogens; Female; Humans; Hydrophobic and Hydrophilic Interactions; Isoflavones; Mice; Mice, Nude; Models, Molecular; Receptors, Progesterone; Response Elements; Structure-Activity Relationship; Transcription, Genetic; Xenograft Model Antitumor Assays | 2010 |
Biomimetic syntheses and antiproliferative activities of racemic, natural (-), and unnnatural (+) glyceollin I.
Topics: Antineoplastic Agents; Biomimetics; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Models, Chemical; Ovarian Neoplasms; Prostatic Neoplasms; Pterocarpans; Receptors, Estrogen; Stereoisomerism | 2011 |
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Cell Line, Tumor; Dogs; Drug Discovery; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Heterografts; Humans; Mice; Proteolysis; Rats; Selective Estrogen Receptor Modulators; Small Molecule Libraries; Tamoxifen | 2015 |
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregu
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cinnamates; Clinical Trials, Phase I as Topic; Down-Regulation; Drug Design; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Humans; Indoles; Injections, Intramuscular; X-Ray Diffraction | 2015 |
Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer.
Topics: Acrylates; Administration, Oral; Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Dogs; Drug Discovery; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice, Inbred C57BL; Molecular Docking Simulation; Proteolysis; Tetrahydroisoquinolines | 2017 |
Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity.
Topics: Antineoplastic Agents; Benzoxepins; Crystallography, X-Ray; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Ligands; MCF-7 Cells; Models, Molecular; Molecular Docking Simulation; Proteolysis; Selective Estrogen Receptor Modulators; Structure-Activity Relationship | 2018 |
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Mice; Rats; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |